Jump to content

Sinopharm (company): Difference between revisions

Coordinates: 39°58′29″N 116°20′24″E / 39.9747°N 116.3401°E / 39.9747; 116.3401
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
 
(38 intermediate revisions by 26 users not shown)
Line 1: Line 1:
{{Short description|Chinese state-owned enterprise}}
{{Short description|Chinese state-owned enterprise}}
{{about|the pharmaceutical company|the COVID-19 vaccine that it developed|Sinopharm BIBP COVID-19 vaccine}}
{{Redirect|Sinopharm||Sinopharm (disambiguation)}}
{{other uses|Sinopharm (disambiguation)}}
{{redirect-distinguish|Sinopharm|Sinovac Biotech}}
{{coord|39.9747|116.3401|display=title}}
{{coord|39.9747|116.3401|display=title}}
{{Infobox company
{{Infobox company
| name = China National Pharmaceutical Group
| name = China National Pharmaceutical Group Corporation
| trade_name = Sinopharm
| trade_name = Sinopharm
| logo = Sinopharm logo.png
| logo = China National Pharmaceutical Group Corporation.png
| logo_size =
| logo_size =
| logo_alt = Sinopharm logo, with bilingual name on the right
| logo_alt =
| logo_caption = Sinopharm logo, with bilingual name on the right
| logo_caption =
| logo_padding =
| logo_padding =
| image = Sinopharm Building (20230206145912).jpg
| image =
| image_size =
| image_size =
| image_alt =
| image_alt =
| image_caption =
| image_caption = Headquarters
| type = [[state-owned enterprise]]
| type = [[State-owned enterprise]]
| products = {{hlist|[[Medication|Pharmaceutical drugs]]|[[vaccine]]s}}
| industry =
| industry = {{Ubl
| founded = November 26, 1998
| [[Pharmaceutical industry|Pharmaceutical]]
⚫
| founder =
| [[Biotechnology]]
}}
| founded = {{start date and age|1998|11|26}}
⚫
| founder =
| former_name =
| former_name =
| hq_location = 20 Zhichun Road, Haidian District
| hq_location = 20 Zhichun Road, Haidian District
Line 23: Line 29:
| hq_location_country = China
| hq_location_country = China
| area_served = China, exported worldwide
| area_served = China, exported worldwide
| num_locations =
| num_locations =
| num_locations_year =
| num_locations_year =
| num_employees =
| num_employees_year =
| num_employees_year =
| key_people = Liu Jingzhen (Chairman & [[Party Committee Secretary]])<ref>{{cite web|url=http://www.sinopharm.com/s/1223-3764-36260.html|title=中国医药集团有限公司主要领导调整|publisher=Sinopharm|language=zh}}</ref><ref>{{cite web|url=https://www.bloomberg.com/profile/person/21371288|title=Liu Jingzhen|publisher=Bloomberg|language=en}}</ref>
| key_people = Liu Jingzhen ([[chairman]] & [[Chinese Communist Party Committee Secretary]])<ref>{{cite web|url=http://www.sinopharm.com/s/1223-3764-36260.html|title=中国医药集团有限公司主要领导调整|publisher=Sinopharm|language=zh|access-date=2021-08-24|archive-date=2022-09-08|archive-url=https://web.archive.org/web/20220908065805/http://www.sinopharm.com/s/1223-3764-36260.html|url-status=dead}}</ref><ref>{{cite web|url=https://www.bloomberg.com/profile/person/21371288|title=Liu Jingzhen|publisher=Bloomberg|language=en}}</ref>
| brands =
| brands =
| services =
| services =
| revenue = {{increase}} [[US$]] 96.1 billion (2023)<ref name=Financials>{{cite web |title=Sinopharm |url=https://fortune.com/company/sinopharm/ |website=Fortune Global 500 |publisher=Fortune |access-date=2024-08-24}}</ref>
| revenue ={{increase}} {{CNY|247.110&nbsp;[[1,000,000,000|billion]]}}
| operating_income =
| revenue_year = 2014
| operating_income = {{increase}} {{CNY|8.758&nbsp;billion}}
| net_income = {{increase}} [[US$]] 1.1 billion (2023)<ref name=Financials />
| assets = [[US$]] 82.8 billion (2023)<ref name=Financials />
| income_year = 2014
| num_employees = 202,426 (2023)<ref name=Financials />
| net_income = {{increase}} {{CNY|2.705&nbsp;billion}}
| net_income_year = 2014
| assets = {{increase}} {{CNY|199.192&nbsp;billion}}
| assets_year = 2014
| equity = {{increase}} {{CNY|31.944&nbsp;billion}}
| equity_year = 2014
| owner = [[State-owned Assets Supervision and Administration Commission of the State Council|Chinese&nbsp;central&nbsp;government]]&nbsp;(100%)
| owner = [[State-owned Assets Supervision and Administration Commission of the State Council|Chinese&nbsp;central&nbsp;government]]&nbsp;(100%)
| parent =
| parent = [[State-owned Assets Supervision and Administration Commission of the State Council|SASAC of the State Council]]
| subsid = {{ubl|Sinopharm&nbsp;Industrial&nbsp;Investment&nbsp;(51%)|→ [[Sinopharm Group]] (56.79%)|[[China Traditional Chinese Medicine|Trad. Chinese Medicine]] (37.59%)|[[Shanghai Shyndec Pharmaceutical|Shyndec Pharma.]] (41.62%)|China National Biotec Group (95%)|→ [[Beijing Tiantan Biological Products|Tiantan Biological]] (53.30%)}}
| subsid = {{ubl|Sinopharm&nbsp;Industrial&nbsp;Investment&nbsp;(51%)|→ [[Sinopharm Group]] (56.79%)|[[China Traditional Chinese Medicine|Trad. Chinese Medicine]] (37.59%)|[[Shanghai Shyndec Pharmaceutical|Shyndec Pharma.]] (41.62%)|China National Biotec Group (95%)|→ [[Beijing Tiantan Biological Products|Tiantan Biological]] (53.30%)}}
| rating =
| rating =
| footnotes = in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards<ref>{{cite web|url=http://www.shclearing.com/xxpl/fxpl/scp/201601/t20160119_126134.html|title=中国医药集团总公司2016年度第一期超短期融资券发行披露材料|trans-title=Pospectus of 2016 (batch 1) Ultra-short-term financing of Sinopharm|date=19 January 2016|access-date=22 November 2016|work=Sinopharm|publisher=Shanghai Clearing House|language=zh}}</ref>
| footnotes = in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards<ref>{{cite web|url=http://www.shclearing.com/xxpl/fxpl/scp/201601/t20160119_126134.html|title=中国医药集团总公司2016年度第一期超短期融资券发行披露材料|trans-title=Pospectus of 2016 (batch 1) Ultra-short-term financing of Sinopharm|date=19 January 2016|access-date=22 November 2016|work=Sinopharm|publisher=Shanghai Clearing House|language=zh}}</ref>
| module=
| module = {{Infobox Chinese
{{Chinese
| child=yes
| child=yes
|s=中国医药集团总公司
|s=中国医药集团总公司
Line 58: Line 57:
}}
}}
}}
}}
'''China National Pharmaceutical Group Corporation''' ('''CNPGC'''), commonly referred to as '''Sinopharm''', is a Chinese [[state-owned enterprise]]. The corporation was the indirect major shareholder of publicly traded companies [[Sinopharm Group]] ({{SEHK|01099}}, via a 51–49 joint venture, Sinopharm Industrial Investment, with [[Fosun Pharmaceutical]]), {{ill|China Traditional Chinese Medicine|zh|中國中藥}} ({{SEHK|00570}}, mostly via Sinopharm Group Hongkong Co., Ltd.).<ref>{{cite web|url=http://www.hkexnews.hk/listedco/listconews/SEHK/2016/0428/LTN201604282264.pdf|title=2015 Annual Report|date=28 April 2016|access-date=22 November 2016|work=China Traditional Chinese Medicine|publisher=Hong Kong Stock Exchange}}</ref> [[Shanghai Shyndec Pharmaceutical]] ({{SSE|600420}}, via a wholly owned research institute based in Shanghai) and [[Beijing Tiantan Biological Products]] ({{SSE|600161}}, via China National Biotec Group).
'''China National Pharmaceutical Group Corporation''' ('''CNPGC'''), commonly referred to as '''Sinopharm''', is a Chinese [[state-owned enterprise]]. The corporation was the indirect major shareholder of publicly traded companies [[Sinopharm Group]] ({{SEHK|01099}}, via a 51–49 joint venture, Sinopharm Industrial Investment, with [[Fosun Pharmaceutical]]), {{ill|China Traditional Chinese Medicine|zh|中國中藥}} ({{SEHK|00570}}, mostly via Sinopharm Group Hongkong Co., Ltd.),<ref>{{cite web|url=http://www.hkexnews.hk/listedco/listconews/SEHK/2016/0428/LTN201604282264.pdf|title=2015 Annual Report|date=28 April 2016|access-date=22 November 2016|work=China Traditional Chinese Medicine|publisher=Hong Kong Stock Exchange}}</ref> [[Shanghai Shyndec Pharmaceutical]] ({{SSE|600420}}, via a wholly owned research institute based in Shanghai), and [[Beijing Tiantan Biological Products]] ({{SSE|600161}}, via China National Biotec Group).


China National Pharmaceutical Group was supervised by the [[State-owned Assets Supervision and Administration Commission of the State Council]].<ref>{{cite web |title = 央企名录 (List of Central SOEs) |url = http://www.sasac.gov.cn/n86114/n86137/index.html|website = Official website of SASAC |access-date=3 March 2016 |language = zh}}</ref>
China National Pharmaceutical Group was supervised by the [[State-owned Assets Supervision and Administration Commission of the State Council]].<ref>{{cite web |title = 央企名录 (List of Central SOEs) |url = http://www.sasac.gov.cn/n86114/n86137/index.html|website = Official website of SASAC |access-date=3 March 2016 |language = zh}}</ref>


Sinopharm was ranked 205th in 2016 [[Fortune Global 500]] list.<ref>http://beta.fortune.com/global500/sinopharm-205</ref>
Sinopharm was ranked 109th in the 2021 [[Fortune Global 500]] list.<ref>{{Cite web|url=https://fortune.com/global500/search/?name=Sinopharm|title = Global 500}}</ref>


==History==
==History==
'''China National Pharmaceutical Group Corporation''' ({{zh|s=中国医药集团总公司}}) was founded on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation ({{zh|s=中国医药工业公司}}), China National Pharmaceutical Foreign Trade Corp. ({{zh|s=中国医药对外贸易公司}}) and China National Medical Device ({{zh|s=中国医疗器械工业公司}}). In 2009 it was merged with China National Biotec Group ({{zh|s=中国生物技术集团公司}}).
Sinopharm was founded as '''China National Pharmaceutical Group Corporation''' ({{zh|s=中国医药集团总公司}}) on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation ({{zh|s=中国医药工业公司}}), China National Pharmaceutical Foreign Trade Corp. ({{zh|s=中国医药对外贸易公司}}) and China National Medical Device ({{zh|s=中国医疗器械工业公司}}). In 2009 it was merged with China National Biotec Group ({{zh|s=中国生物技术集团公司}}).{{citation needed|date=October 2022}}


Its subsidiary Wuhan Institute of Biological Products was fined for selling 400,520 ineffective [[DPT vaccine]]s in November 2017.<ref>{{cite news|date=23 July 2018|title=Chinese President Xi Jinping orders crackdown over 'appalling' vaccine scandal|publisher=South China Morning Post|url=https://www.scmp.com/news/china/policies-politics/article/2156431/chinese-premier-li-keqiang-promises-clean-vaccine|access-date=29 November 2018}}</ref>
Its subsidiary Wuhan Institute of Biological Products was fined for selling 400,520 ineffective [[DPT vaccine]]s in November 2017.<ref>{{cite news|date=23 July 2018|title=Chinese President Xi Jinping orders crackdown over 'appalling' vaccine scandal|publisher=South China Morning Post|url=https://www.scmp.com/news/china/policies-politics/article/2156431/chinese-premier-li-keqiang-promises-clean-vaccine|access-date=29 November 2018}}</ref>


[[Pfizer]] announced the signing of a cooperation pact with Sinopharm Group in April 2023, with plans to seep approval for 12 drugs in China through 2025.<ref>{{Cite news |date=2023-04-13 |title=Pfizer signs strategic cooperation pact with China's Sinopharm |language=en |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-signs-strategic-cooperation-pact-with-chinas-sinopharm-2023-04-13/ |access-date=2023-11-08}}</ref>
⚫
==COVID-19 vaccine==

{{main|Sinopharm BIBP COVID-19 vaccine}}
⚫
==COVID-19 vaccines==
{{main|Sinopharm BIBP COVID-19 vaccine|Sinopharm WIBP COVID-19 vaccine|Sinopharm CNBG COVID-19 vaccine}}


'''Sinopharm BBIBP-CorV''', also known as the '''Sinopharm COVID-19 vaccine''',<ref>[https://www.nytimes.com/interactive/2020/health/sinopharm-covid-19-vaccine.html How the Sinopharm Vaccine Works] Jonathan Corum and Carl Zimmer 22 March 2021, ''www.nytimes.com'', accessed 11 April 2021</ref> is one of two [[Inactivated vaccine|inactivated virus]] [[COVID-19 vaccine|COVID-19 vaccines]] developed by [[Sinopharm]]. It completed [[Phases of clinical research#Phase III|Phase III trials]] in [[Argentina]], [[Bahrain]], [[Egypt]], [[Morocco]], [[Pakistan]], [[Peru]], and the [[United Arab Emirates]] (UAE) with over 60,000 participants.<ref name=":52">{{Cite news|author=Reuters Staff|date=2020-11-19|title=China Sinopharm's coronavirus vaccine taken by about a million people in emergency use|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-vaccine-sinopharm-idUSKBN27Z0PY|access-date=2020-12-09}}</ref> BBIBP-CorV shares similar technology with [[CoronaVac]] and [[BBV152]], other inactivated virus vaccines for COVID-19.<ref name=":27">{{cite news|last1=Corum|first1=Jonathan|last2=Zimmer|first2=Carl|date=2021-04-26|title=How the Sinopharm Vaccine Works|work=The New York Times|url=https://www.nytimes.com/interactive/2020/health/sinopharm-covid-19-vaccine.html|access-date=2021-04-29|issn=0362-4331}}</ref>
The '''Sinopharm BIBP COVID-19 vaccine''', also known as '''BBIBP-CorV''',<ref name=":0">{{cite journal | vauthors = Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X | display-authors = 6 | title = Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial | journal = The Lancet. Infectious Diseases | volume = 21 | issue = 1 | pages = 39–51 | date = January 2021 | pmid = 33069281 | pmc = 7561304 | doi = 10.1016/s1473-3099(20)30831-8 }}</ref> the '''Sinopharm COVID-19 vaccine''',<ref name="who-faq">{{cite news |title=The Sinopharm COVID-19 vaccine: What you need to know |url=https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know |access-date=5 July 2021 |publisher=World Health Organization |date=10 May 2021}}</ref> or '''BIBP vaccine''',<ref name="who-faq"/><ref>{{cite news | vauthors = Nguyen S |title=Coronavirus: Vietnam approves Sinopharm's vaccine, but will people take it? |url=https://www.scmp.com/week-asia/health-environment/article/3136137/coronavirus-vietnam-approves-sinopharms-vaccine-will |access-date=5 July 2021 |work=South China Morning Post |date=5 June 2021}}</ref><ref>{{cite news | vauthors = Lahiri T, Li J |title=What we now know about the efficacy of China's Covid-19 vaccines |url=https://qz.com/2018838/what-we-know-about-efficacy-of-sinopharm-sinovac-vaccines/ |access-date=5 July 2021 |work=Quartz |date=16 June 2021}}</ref> is one of two [[Inactivated vaccine|inactivated virus]] [[COVID-19 vaccine]]s developed by [[Sinopharm]]. It completed [[Phases of clinical research#Phase III|Phase III trials]] in [[Argentina]], [[Bahrain]], [[Egypt]], [[Morocco]], [[Pakistan]], [[Peru]], and the [[United Arab Emirates]] (UAE) with over 60,000 participants.<ref name=":52">{{Cite news|last1=Liu|first1=Roxanne|last2=Munroe|first2=Tony|editor-last=Sarkar|editor-first=Himani|date=2020-11-19|title=China Sinopharm's coronavirus vaccine taken by about a million people in emergency use|work=Reuters|location=Beijing|url=https://www.reuters.com/article/us-health-coronavirus-vaccine-sinopharm-idUSKBN27Z0PY|access-date=2023-01-19}}</ref> BBIBP-CorV shares similar technology with [[CoronaVac]] and [[BBV152]], other inactivated virus vaccines for COVID-19.<ref name=":27">{{cite news|last1=Corum|first1=Jonathan|last2=Zimmer|first2=Carl|date=2021-04-26|title=How the Sinopharm Vaccine Works|work=The New York Times|url=https://www.nytimes.com/interactive/2020/health/sinopharm-covid-19-vaccine.html|access-date=2021-04-29|issn=0362-4331}}</ref>


Peer-reviewed results published in [[JAMA]] of Phase III trials in [[United Arab Emirates]] and [[Bahrain]] showed BBIBP-CorV 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).<ref name="jama.2021.8565">{{cite journal|last1=Kaabi|first1=Nawal Al|last2=Zhang|first2=Yuntao|last3=Xia|first3=Shengli|last4=Yang|first4=Yunkai|last5=Qahtani|first5=Manaf M. Al|last6=Abdulrazzaq|first6=Najiba|last7=Nusair|first7=Majed Al|last8=Hassany|first8=Mohamed|last9=Jawad|first9=Jaleela S.|last10=Abdalla|first10=Jehad|last11=Hussein|first11=Salah Eldin|display-authors=3|date=May 26, 2021|title=Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial|journal=JAMA|language=en|doi=10.1001/jama.2021.8565|first29=Yuxiu|first22=Yang|first16=Wei|last17=Lai|first17=Bonan|last18=Chen|first18=Wei|last19=Huang|first19=Shihe|last20=Wang|first20=Qian|last21=Yang|first21=Tian|last22=Liu|last23=Ma|last29=Zhao|last30=Jiang|first14=Xinguo|last24=Hussain|first24=Zaidoon M.|last25=Khan|first25=Tehmina|last26=Fasihuddin|first26=Mohammed Saifuddin|last27=You|first27=Wangyang|last28=Xie|first28=Zhiqiang|last16=Wang|last31=Zhao|first15=Xuqin|last37=Zaher|last15=Yang|first37=Walid Abbas|last32=Zhang|first32=Yanbo|last33=Mahmoud|first33=Sally|last34=ElTantawy|first34=Islam|last35=Xiao|first35=Peng|last36=Koshy|first36=Ashish|first38=Hui|first30=Zhiwei|last38=Wang|last39=Duan|first39=Kai|last40=Pan|first40=An|last41=Yang|first41=Xiaoming|last14=Li|first13=Maysoon Al|last13=Karam|first12=Shamma K. Al|last12=Mazrouei|first31=Guoqing|first23=Rui|volume=326|issue=1|pages=35–45|pmid=34037666|pmc=8156175|doi-access=free|pmc-embargo-date=November 26, 2021}}</ref> In December 2020, the UAE previously announced interim results showing 86% efficacy.<ref>{{Cite web|title=UAE: Ministry of Health announces 86 per cent vaccine efficacy|url=https://gulfnews.com/uae/health/uae-ministry-of-health-announces-86-per-cent-vaccine-efficacy-1.1607490555571|access-date=2020-12-13|website=gulfnews.com|language=en}}</ref> While mRNA vaccines like the [[Pfizer–BioNTech COVID-19 vaccine]] and [[mRNA-1273]] showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.<ref name=":62">{{Cite news|date=2020-12-09|title=China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says|language=en|work=Bloomberg.com|url=https://www.bloomberg.com/news/articles/2020-12-09/uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19|access-date=2020-12-09}}</ref>
Peer-reviewed results published in [[JAMA]] of Phase III trials in [[United Arab Emirates]] and [[Bahrain]] showed BBIBP-CorV 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).<ref name="jama.2021.8565">{{cite journal|last1=Kaabi|first1=Nawal Al|last2=Zhang|first2=Yuntao|last3=Xia|first3=Shengli|last4=Yang|first4=Yunkai|last5=Qahtani|first5=Manaf M. Al|last6=Abdulrazzaq|first6=Najiba|last7=Nusair|first7=Majed Al|last8=Hassany|first8=Mohamed|last9=Jawad|first9=Jaleela S.|last10=Abdalla|first10=Jehad|last11=Hussein|first11=Salah Eldin|display-authors=3|date=May 26, 2021|title=Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial|journal=JAMA|language=en|doi=10.1001/jama.2021.8565|first29=Yuxiu|first22=Yang|first16=Wei|last17=Lai|first17=Bonan|last18=Chen|first18=Wei|last19=Huang|first19=Shihe|last20=Wang|first20=Qian|last21=Yang|first21=Tian|last22=Liu|last23=Ma|last29=Zhao|last30=Jiang|first14=Xinguo|last24=Hussain|first24=Zaidoon M.|last25=Khan|first25=Tehmina|last26=Fasihuddin|first26=Mohammed Saifuddin|last27=You|first27=Wangyang|last28=Xie|first28=Zhiqiang|last16=Wang|last31=Zhao|first15=Xuqin|last37=Zaher|last15=Yang|first37=Walid Abbas|last32=Zhang|first32=Yanbo|last33=Mahmoud|first33=Sally|last34=ElTantawy|first34=Islam|last35=Xiao|first35=Peng|last36=Koshy|first36=Ashish|first38=Hui|first30=Zhiwei|last38=Wang|last39=Duan|first39=Kai|last40=Pan|first40=An|last41=Yang|first41=Xiaoming|last14=Li|first13=Maysoon Al|last13=Karam|first12=Shamma K. Al|last12=Mazrouei|first31=Guoqing|first23=Rui|volume=326|issue=1|pages=35–45|pmid=34037666|pmc=8156175|doi-access=free}}</ref> In December 2020, the UAE previously announced interim results showing 86% efficacy.<ref>{{Cite web|title=UAE: Ministry of Health announces 86 per cent vaccine efficacy|url=https://gulfnews.com/uae/health/uae-ministry-of-health-announces-86-per-cent-vaccine-efficacy-1.1607490555571|access-date=2020-12-13|website=gulfnews.com|date=9 December 2020 |language=en}}</ref> While mRNA vaccines like the [[Pfizer–BioNTech COVID-19 vaccine]] and [[mRNA-1273]] showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.<ref name=":62">{{Cite news|date=2020-12-09|title=China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says|language=en|work=Bloomberg.com|url=https://www.bloomberg.com/news/articles/2020-12-09/uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19|access-date=2020-12-09}}</ref>


BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia,<ref name=":122">{{Cite news|date=2020-12-31|title=China gives its first COVID-19 vaccine approval to Sinopharm|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-vaccine-china-idUSKBN29505P|url-status=live|access-date=2020-12-31|vauthors=Liu R}}</ref><ref name=":26">{{Cite web|last=Turak|first=Natasha|date=2021-01-18|title=The UAE is on track to have half its population vaccinated by the end of March|url=https://www.cnbc.com/2021/01/18/uae-on-track-to-vaccinate-half-its-population-by-end-of-march-.html|access-date=2021-01-21|website=CNBC}}</ref><ref name=":72">{{Cite web|last=Dawn.com|date=2021-02-02|title=PM Imran kicks off Pakistan's Covid-19 vaccination drive|url=https://www.dawn.com/news/1605089|access-date=2021-02-03|website=DAWN.COM|language=en}}</ref> Africa,<ref name=":92">{{Cite news|author=Reuters Staff|date=2021-01-24|title=Sisi says Egypt to begin COVID-19 vaccinations on Sunday|work=[[Reuters]]|url=https://www.reuters.com/article/us-health-coronavirus-egypt-vaccinations-idUSKBN29T05N|access-date=2021-01-24}}</ref><ref name=":152">{{Cite web|last=Dumpis|first=Toms|date=2021-01-27|title=Morocco Receives Half a Million Doses of Chinese Sinopharm Vaccine|url=https://www.moroccoworldnews.com/2021/01/333436/morocco-receives-half-a-million-doses-of-chinese-sinopharm-vaccine/|access-date=2021-01-28|website=Morocco World News}}</ref><ref name=":112">{{Cite web|date=2021-02-18|title=Zimbabwe starts administering China's Sinopharm vaccines|url=https://www.thestar.com/news/world/africa/2021/02/18/zimbabwe-starts-administering-chinas-sinopharm-vaccines.html|access-date=2021-02-20|website=thestar.com|language=en}}</ref> South America,<ref name=":252">{{Cite web|title=Argentina autoriza la vacuna china Sinopharm para mayores de 60 años|url=https://www.elcomercio.com/actualidad/argentina-vacuna-china-sinopharm-adultos.html|access-date=2021-03-26|website=El Comercio}}</ref><ref name=":162">{{Cite news|last=Aquino|first=Marco|date=2021-02-10|title='The best shield': Peru launches inoculation drive with Sinopharm vaccine|language=en|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-peru-vaccine-idUSKBN2AA03U|access-date=2021-02-10}}</ref><ref name=":232">{{Cite web|title=Bolivia begins inoculation with Sinopharm jabs {{!}} The Star|url=https://www.thestar.com.my/aseanplus/aseanplus-news/2021/02/26/bolivia-begins-inoculation-with-sinopharm-jabs|access-date=2021-02-28|website=www.thestar.com.my}}</ref> and Europe.<ref name=":172">{{Cite web|title=Serbia Becomes First European Nation To Use China's Sinopharm Vaccine|url=https://www.rferl.org/a/serbia-covid-vaccine-china-sinopharm/31053091.html|access-date=2021-01-21|website=RadioFreeEurope/RadioLiberty}}</ref><ref name=":212">{{Cite web|date=2021-02-24|title=Hungary first EU nation to use China's Sinopharm vaccine against COVID|url=https://www.euronews.com/2021/02/24/hungary-becomes-first-eu-nation-to-use-china-s-sinopharm-vaccine-against-covid-19|access-date=2021-02-26|website=euronews|language=en}}</ref><ref name=":242">{{Cite web|date=2021-03-15|title=Belarus begins COVID-19 vaccinations with Chinese shots|url=https://eng.belta.by/society/view/belarus-begins-covid-19-vaccinations-with-chinese-shots-138222-2021/|access-date=2021-03-16|website=eng.belta.by|language=en-EN}}</ref> Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021.<ref name=":222">{{Cite web|date=2021-02-05|title=Which companies will likely produce the most COVID-19 vaccine in 2021?|url=https://www.pharmaceuticalprocessingworld.com/which-companies-will-likely-produce-the-most-covid-19-vaccine-in-2021/|access-date=2021-02-28|website=Pharmaceutical Processing World|language=en-US}}</ref> On 7 May 2021, the [[World Health Organization]] approved the vaccine for emergency use<ref name="WHOEUA">{{cite news|last=Taylor|first=Adam|date=7 May 2021|title=WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine|website=[[The Washington Post]]|url=https://www.washingtonpost.com/world/2021/05/07/who-sinopharm-emergency-use/|access-date=7 May 2021}}</ref> and Sinopharm later signed purchase agreements for 170 million doses from [[COVAX]].<ref name=":282">{{Cite web|date=2021-07-12|title=Chinese drugmakers agree to supply more than half a billion vaccines to COVAX|url=https://www.reuters.com/world/gavi-signs-covid-19-vaccine-supply-deals-with-sinovac-sinopharm-covax-2021-07-12/|access-date=2021-07-13|website=Reuters}}</ref>
BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia,<ref name=":122">{{Cite news|date=2020-12-31|title=China gives its first COVID-19 vaccine approval to Sinopharm|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-vaccine-china-idUSKBN29505P|access-date=2020-12-31|vauthors=Liu R}}</ref><ref name=":26">{{Cite web|last=Turak|first=Natasha|date=2021-01-18|title=The UAE is on track to have half its population vaccinated by the end of March|url=https://www.cnbc.com/2021/01/18/uae-on-track-to-vaccinate-half-its-population-by-end-of-march-.html|access-date=2021-01-21|website=CNBC}}</ref><ref name=":72">{{Cite web|last=Dawn.com|date=2021-02-02|title=PM Imran kicks off Pakistan's Covid-19 vaccination drive|url=https://www.dawn.com/news/1605089|access-date=2021-02-03|website=DAWN.COM|language=en}}</ref> Africa,<ref name=":92">{{Cite news|last1=Waly|first1=Mohamed|last2=Eltahir|first2=Nafisa|editor-last=Richardson|editor-first=Alex|date=2021-01-24|title=Sisi says Egypt to begin COVID-19 vaccinations on Sunday|work=[[Reuters]]|location=Cairo|url=https://www.reuters.com/article/us-health-coronavirus-egypt-vaccinations-idUSKBN29T05N|access-date=2023-01-19}}</ref><ref name=":152">{{Cite web|last=Dumpis|first=Toms|date=2021-01-27|title=Morocco Receives Half a Million Doses of Chinese Sinopharm Vaccine|url=https://www.moroccoworldnews.com/2021/01/333436/morocco-receives-half-a-million-doses-of-chinese-sinopharm-vaccine/|access-date=2021-01-28|website=Morocco World News}}</ref><ref name=":112">{{Cite web|date=2021-02-18|title=Zimbabwe starts administering China's Sinopharm vaccines|url=https://www.thestar.com/news/world/africa/2021/02/18/zimbabwe-starts-administering-chinas-sinopharm-vaccines.html|access-date=2021-02-20|website=thestar.com|language=en}}</ref> South America,<ref name=":252">{{Cite web|title=Argentina autoriza la vacuna china Sinopharm para mayores de 60 años|url=https://www.elcomercio.com/actualidad/argentina-vacuna-china-sinopharm-adultos.html|access-date=2021-03-26|website=El Comercio}}</ref><ref name=":162">{{Cite news|last=Aquino|first=Marco|date=2021-02-10|title='The best shield': Peru launches inoculation drive with Sinopharm vaccine|language=en|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-peru-vaccine-idUSKBN2AA03U|access-date=2021-02-10}}</ref><ref name=":232">{{Cite web|title=Bolivia begins inoculation with Sinopharm jabs {{!}} The Star|url=https://www.thestar.com.my/aseanplus/aseanplus-news/2021/02/26/bolivia-begins-inoculation-with-sinopharm-jabs|access-date=2021-02-28|website=www.thestar.com.my}}</ref> and Europe.<ref name=":172">{{Cite news|title=Serbia Becomes First European Nation To Use China's Sinopharm Vaccine|url=https://www.rferl.org/a/serbia-covid-vaccine-china-sinopharm/31053091.html|access-date=2021-01-21|newspaper=Radio Free Europe/Radio Liberty|date=20 January 2021 }}</ref><ref name=":212">{{Cite web|date=2021-02-24|title=Hungary first EU nation to use China's Sinopharm vaccine against COVID|url=https://www.euronews.com/2021/02/24/hungary-becomes-first-eu-nation-to-use-china-s-sinopharm-vaccine-against-covid-19|access-date=2021-02-26|website=euronews|language=en}}</ref><ref name=":242">{{Cite web|date=2021-03-15|title=Belarus begins COVID-19 vaccinations with Chinese shots|url=https://eng.belta.by/society/view/belarus-begins-covid-19-vaccinations-with-chinese-shots-138222-2021/|access-date=2021-03-16|website=eng.belta.by|language=en-EN}}</ref> Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021.<ref name=":222">{{Cite web|date=2021-02-05|title=Which companies will likely produce the most COVID-19 vaccine in 2021?|url=https://www.pharmaceuticalprocessingworld.com/which-companies-will-likely-produce-the-most-covid-19-vaccine-in-2021/|access-date=2021-02-28|website=Pharmaceutical Processing World|language=en-US}}</ref> On 7 May 2021, the [[World Health Organization]] approved the vaccine for emergency use<ref name="WHOEUA">{{cite news|last=Taylor|first=Adam|date=7 May 2021|title=WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine|newspaper=[[The Washington Post]]|url=https://www.washingtonpost.com/world/2021/05/07/who-sinopharm-emergency-use/|access-date=7 May 2021}}</ref> and Sinopharm later signed purchase agreements for 170 million doses from [[COVAX]].<ref name=":282">{{Cite web|date=2021-07-12|title=Chinese drugmakers agree to supply more than half a billion vaccines to COVAX|url=https://www.reuters.com/world/gavi-signs-covid-19-vaccine-supply-deals-with-sinovac-sinopharm-covax-2021-07-12/|access-date=2021-07-13|website=Reuters}}</ref>


The similarly named Sinopharm WIBP COVID-19 vaccine is also an inactivated virus vaccine.{{citation needed|date=October 2022}}
The other inactivated virus COVID-19 vaccine developed by Sinopharm is [[WIBP-CorV]].


==See also==
==See also==
Line 98: Line 99:
[[Category:Companies based in Beijing]]
[[Category:Companies based in Beijing]]
[[Category:Chinese companies established in 1998]]
[[Category:Chinese companies established in 1998]]
[[Category:COVID-19 vaccine producers]]

Latest revision as of 18:37, 20 October 2024

This article is about the pharmaceutical company. For the COVID-19 vaccine that it developed, see Sinopharm BIBP COVID-19 vaccine.
For other uses, see Sinopharm (disambiguation).
"Sinopharm" redirects here. Not to be confused with Sinovac Biotech.

39°58′29″N 116°20′24″E / 39.9747°N 116.3401°E / 39.9747; 116.3401

China National Pharmaceutical Group Corporation
Sinopharm
Company typeState-owned enterprise
Industry
FoundedNovember 26, 1998; 26 years ago (1998-11-26)
Headquarters20 Zhichun Road, Haidian District,
Beijing
,
China
Area served
China, exported worldwide
Key people
Liu Jingzhen (chairman & Chinese Communist Party Committee Secretary)[1][2]
Products
RevenueIncrease US$ 96.1 billion (2023)[3]
Increase US$ 1.1 billion (2023)[3]
Total assetsUS$ 82.8 billion (2023)[3]
OwnerChinese central government (100%)
Number of employees
202,426 (2023)[3]
Subsidiaries
Chinese name
Simplified Chinese中国医药集团总公司
Traditional Chinese中國醫藥集團總公司
Transcriptions
Standard Mandarin
Hanyu PinyinZhōngguó yīyào jítuán zǒng gōngsī
short Chinese name
Simplified Chinese国药集团
Traditional Chinese國藥集團
Transcriptions
Standard Mandarin
Hanyu PinyinGuóyào jítuán
Footnotes / references
in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards[4]

China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine [zh] (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.),[5] Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai), and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).

China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.[6]

Sinopharm was ranked 109th in the 2021 Fortune Global 500 list.[7]

History

[edit]

Sinopharm was founded as China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China National Medical Device (Chinese: 中国医疗器械工业公司). In 2009 it was merged with China National Biotec Group (Chinese: 中国生物技术集团公司).[citation needed]

Its subsidiary Wuhan Institute of Biological Products was fined for selling 400,520 ineffective DPT vaccines in November 2017.[8]

Pfizer announced the signing of a cooperation pact with Sinopharm Group in April 2023, with plans to seep approval for 12 drugs in China through 2025.[9]

COVID-19 vaccines

[edit]
Main articles: Sinopharm BIBP COVID-19 vaccine, Sinopharm WIBP COVID-19 vaccine, and Sinopharm CNBG COVID-19 vaccine

The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV,[10] the Sinopharm COVID-19 vaccine,[11] or BIBP vaccine,[11][12][13] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[14] BBIBP-CorV shares similar technology with CoronaVac and BBV152, other inactivated virus vaccines for COVID-19.[15]

Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed BBIBP-CorV 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).[16] In December 2020, the UAE previously announced interim results showing 86% efficacy.[17] While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and mRNA-1273 showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.[18]

BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia,[19][20][21] Africa,[22][23][24] South America,[25][26][27] and Europe.[28][29][30] Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021.[31] On 7 May 2021, the World Health Organization approved the vaccine for emergency use[32] and Sinopharm later signed purchase agreements for 170 million doses from COVAX.[33]

The similarly named Sinopharm WIBP COVID-19 vaccine is also an inactivated virus vaccine.[citation needed]

See also

[edit]

References

[edit]
  1. ^ "中国医药集团有限公司主要领导调整" (in Chinese). Sinopharm. Archived from the original on 2022-09-08. Retrieved 2021-08-24.
  2. ^ "Liu Jingzhen". Bloomberg.
  3. ^ a b c d "Sinopharm". Fortune Global 500. Fortune. Retrieved 2024-08-24.
  4. ^ "中国医药集团总公司2016年度第一期超短期融资券发行披露材料" [Pospectus of 2016 (batch 1) Ultra-short-term financing of Sinopharm]. Sinopharm (in Chinese). Shanghai Clearing House. 19 January 2016. Retrieved 22 November 2016.
  5. ^ "2015 Annual Report" (PDF). China Traditional Chinese Medicine. Hong Kong Stock Exchange. 28 April 2016. Retrieved 22 November 2016.
  6. ^ "央企名录 (List of Central SOEs)". Official website of SASAC (in Chinese). Retrieved 3 March 2016.
  7. ^ "Global 500".
  8. ^ "Chinese President Xi Jinping orders crackdown over 'appalling' vaccine scandal". South China Morning Post. 23 July 2018. Retrieved 29 November 2018.
  9. ^ "Pfizer signs strategic cooperation pact with China's Sinopharm". Reuters. 2023-04-13. Retrieved 2023-11-08.
  10. ^ Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. (January 2021). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial". The Lancet. Infectious Diseases. 21 (1): 39–51. doi:10.1016/s1473-3099(20)30831-8. PMC 7561304. PMID 33069281.
  11. ^ a b "The Sinopharm COVID-19 vaccine: What you need to know". World Health Organization. 10 May 2021. Retrieved 5 July 2021.
  12. ^ Nguyen S (5 June 2021). "Coronavirus: Vietnam approves Sinopharm's vaccine, but will people take it?". South China Morning Post. Retrieved 5 July 2021.
  13. ^ Lahiri T, Li J (16 June 2021). "What we now know about the efficacy of China's Covid-19 vaccines". Quartz. Retrieved 5 July 2021.
  14. ^ Liu, Roxanne; Munroe, Tony (2020-11-19). Sarkar, Himani (ed.). "China Sinopharm's coronavirus vaccine taken by about a million people in emergency use". Reuters. Beijing. Retrieved 2023-01-19.
  15. ^ Corum, Jonathan; Zimmer, Carl (2021-04-26). "How the Sinopharm Vaccine Works". The New York Times. ISSN 0362-4331. Retrieved 2021-04-29.
  16. ^ Kaabi, Nawal Al; Zhang, Yuntao; Xia, Shengli; et al. (May 26, 2021). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. 326 (1): 35–45. doi:10.1001/jama.2021.8565. PMC 8156175. PMID 34037666.
  17. ^ "UAE: Ministry of Health announces 86 per cent vaccine efficacy". gulfnews.com. 9 December 2020. Retrieved 2020-12-13.
  18. ^ "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg.com. 2020-12-09. Retrieved 2020-12-09.
  19. ^ Liu R (2020-12-31). "China gives its first COVID-19 vaccine approval to Sinopharm". Reuters. Retrieved 2020-12-31.
  20. ^ Turak, Natasha (2021-01-18). "The UAE is on track to have half its population vaccinated by the end of March". CNBC. Retrieved 2021-01-21.
  21. ^ Dawn.com (2021-02-02). "PM Imran kicks off Pakistan's Covid-19 vaccination drive". DAWN.COM. Retrieved 2021-02-03.
  22. ^ Waly, Mohamed; Eltahir, Nafisa (2021-01-24). Richardson, Alex (ed.). "Sisi says Egypt to begin COVID-19 vaccinations on Sunday". Reuters. Cairo. Retrieved 2023-01-19.
  23. ^ Dumpis, Toms (2021-01-27). "Morocco Receives Half a Million Doses of Chinese Sinopharm Vaccine". Morocco World News. Retrieved 2021-01-28.
  24. ^ "Zimbabwe starts administering China's Sinopharm vaccines". thestar.com. 2021-02-18. Retrieved 2021-02-20.
  25. ^ "Argentina autoriza la vacuna china Sinopharm para mayores de 60 años". El Comercio. Retrieved 2021-03-26.
  26. ^ Aquino, Marco (2021-02-10). "'The best shield': Peru launches inoculation drive with Sinopharm vaccine". Reuters. Retrieved 2021-02-10.
  27. ^ "Bolivia begins inoculation with Sinopharm jabs | The Star". www.thestar.com.my. Retrieved 2021-02-28.
  28. ^ "Serbia Becomes First European Nation To Use China's Sinopharm Vaccine". Radio Free Europe/Radio Liberty. 20 January 2021. Retrieved 2021-01-21.
  29. ^ "Hungary first EU nation to use China's Sinopharm vaccine against COVID". euronews. 2021-02-24. Retrieved 2021-02-26.
  30. ^ "Belarus begins COVID-19 vaccinations with Chinese shots". eng.belta.by. 2021-03-15. Retrieved 2021-03-16.
  31. ^ "Which companies will likely produce the most COVID-19 vaccine in 2021?". Pharmaceutical Processing World. 2021-02-05. Retrieved 2021-02-28.
  32. ^ Taylor, Adam (7 May 2021). "WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine". The Washington Post. Retrieved 7 May 2021.
  33. ^ "Chinese drugmakers agree to supply more than half a billion vaccines to COVAX". Reuters. 2021-07-12. Retrieved 2021-07-13.
[edit]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Sinopharm_(company)&oldid=1252297487"